Compare HTBK & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTBK | ESPR |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | 304 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 667.4M | 898.5M |
| IPO Year | 1998 | 2013 |
| Metric | HTBK | ESPR |
|---|---|---|
| Price | $11.96 | $3.84 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $11.88 | $6.86 |
| AVG Volume (30 Days) | 361.3K | ★ 6.7M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | $187,676,000.00 | ★ $303,802,000.00 |
| Revenue This Year | $13.16 | $25.45 |
| Revenue Next Year | $7.61 | N/A |
| P/E Ratio | $16.48 | ★ N/A |
| Revenue Growth | ★ 10.94 | 2.83 |
| 52 Week Low | $8.09 | $0.69 |
| 52 Week High | $11.71 | $4.03 |
| Indicator | HTBK | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 76.48 | 63.33 |
| Support Level | $11.06 | $3.68 |
| Resistance Level | $11.48 | $4.00 |
| Average True Range (ATR) | 0.26 | 0.24 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 96.53 | 83.06 |
Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.